David Llewellyn (L) and Joe Illingworth, DJS Antibodies co-founders
October 20, 2022 10:45 AM EDT
Deals

Ab­b­Vie re­cruits a GPCR team in Ox­ford, buy­ing out a fledg­ling biotech for $255M+

John Carroll

Editor & Founder

Less than 2 years af­ter some Ox­ford grads pieced to­geth­er a lit­tle £6 mil­lion seed fund to launch their dis­cov­ery out­fit, the an­ti­body de­vel­op­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times